Cannabis magazine on EXCLUSIVE IMPORT from Canada.
Hemp
Cannabis magazine on EXCLUSIVE IMPORT from Canada.
Hemp Gazette is doing a intresting piece, enjoy.
QBL subsidiary MCL has inked a deal with Canada’s Canntab Therapeutics to bring Canntab XR tablets into Australia.
The tablets are designed to deliver cannabinoids over a number of hours and have varying levels of THC and/or CBD. The company says the tablets take the guesswork out of cannabis medicines, which will make doctors more comfortable in prescribing them.
The enthusiastic announcement from QBL regarding the joint venture agreement claims Canntab is a “game-changing” medicine.
“Everyone knows someone who could benefit from this new technology,” said Pnina Feldman, QBL Executive Chairperson.
Canntab CEO Jeff Renwick says the deal enables the company to bring a significant advancement in cannabis-based medicines to Australia. The company will also have first rights to distribute the products throughout Asia, that can be a huge market for QBL.
“We believe that the patents filed and pending protects key features of our IP, and positions Canntab to be the definitive Cannabis delivery method of choice among the established medical professions and ever- expanding number of Australians using cannabis every day for medical purposes, and an even greater number who would find benefits from its use,” states the announcement.
Each of Canntab’s five products is available in different dosage levels (2.5mg, 5mg, and 10mg) and in instant and stable extended release. The extended-release products are designed to release the active pharmaceutical ingredient at a predetermined rate in order to maintain a constant concentration over a specific period of time; which could be up to 18 hours.
Four of the products contain THC or THC and CBD, while Canntab “Yellow” tablets only contain CBD. It’s been a busy couple of weeks for Medical Cannabis Limited. Late last month we reported it had teamed up with Australia’s Algae.Tec Ltd (ASX:AEB) in a project researching cannabis-based veterinary medications.
ABOUT US
Hemp Gazette is a medicinal marijuana and industrial hemp information website. Based in Australia, we publish the latest breaking legal, medical and business news, research and industry reports from around the world.
See QBL-board and website for latest updates.
https://www.queenslandbauxite.com/
Here you have the possibility to take advantage on facts and info from QBL. Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Contact information to the QBL Investor service, who can reply on questions and clear up things if wondering.
Robert
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...
Continue Reading
What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...
Continue Reading
Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....
Continue Reading
Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...
Continue Reading
Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....
Continue Reading
Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...
Continue Reading
Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...
Continue Reading
Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...
Continue Reading
Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...
Continue Reading
Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...
Continue Reading
Top 5 Most Recently Viewed Articles
APh ePower's Remarkable Innovation Award The leader in aluminum battery technology is not only setting standards for efficiency but is also making strides in sustainability. Recently, APh ePower was honored with the prestigious 2025 R&D 100 Award for its groundbreaking Elevator Regenerative Power System (ERPS). This award highlights the company's efforts in redefining...
Continue Reading
Butterfly Completes Major Dividend Recapitalization Butterfly, a well-known private equity firm based in Los Angeles, has made a significant move in the food industry by securing a substantial $300 million second lien term loan facility. This funding is intended to support Milk Specialties Global, an important portfolio company recognized for its innovative methods in...
Continue Reading
Rezolve Ai Introduces Key Updates to BRAiN Assistant Rezolve Ai (Nasdaq: RZLV) has made a bold move in the realm of AI technology with a substantial update to its BRAiN Assistant. This upgraded platform is designed to significantly enhance user experience and response accuracy, reinforcing the company's dedication to harnessing innovative technology for superior AI-driven...
Continue Reading
The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...
Continue Reading
Encouraging Developments in Cancer Treatment by Vir Biotechnology Vir Biotechnology, Inc. (NASDAQ: VIR) has recently shared commendable initial Phase 1 data regarding their innovative dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500. These breakthroughs target challenging forms of cancer, notably HER2-expressing solid tumors and metastatic castration-resistant...
Continue Reading